are geographic differences in the prevalence of BrS: it varies from 0.5 to 4 per 1,000 in Asian countries such as Thailand, the Philippines, Japan, and Singapore (Rattanawong et al., 2016; Rattanawong, Ngarmukos, et al., 2017) , whereas the prevalence is less than 0.2 per 1,000 in the western hemisphere (Kamakura, 2013) . It is more common in men and can be induced by fever, with the prevalence of fever-induced BrS of approximately 2%-4% (Kamakura, 2013; Rattanawong et al., 2016) .
The most common identifiable genetic defect in BrS lies in the SCN5A gene, which encodes the α-subunit of the NaV1.5 cardiac sodium channel and accounts for 14%-26% of the cases (Chen et al., 1998; Yamagata et al., 2017) . More than 300 mutations in the SCN5A gene have been linked to the syndrome (Juang & Horie, 2016) . The only preventive measure for sudden cardiac death in BrS is ICD implantation; thus, risk stratification to select the patient in whom ICD is appropriate is crucial (Probst et al., 2010) . The use of SCN5A mutation status to prognosticate the risk of MAE in BrS patients has been controversial (Adler et al., 2016) : some studies showed positive results (Makarawate et al., 2017; Nishii et al., 2010; Yamagata et al., 2017) , while others failed to correlate the mutation to subsequent MAE (Andorin et al., 2016; Gehi, Duong, Metz, Gomes, & Mehta, 2006; Priori et al., 2002; Probst et al., 2010) . The goal of this systematic review and meta-analysis was to examine the association of SCN5A mutations and MAE in BrS patients.
| ME THOD

| Search strategy
Two investigators (WV and PC) independently searched for published studies indexed in MEDLINE and EMBASE databases from inception to September 2017 using a search strategy that included the terms "SCN5A," "mutation," and "Brugada." Only English language publications were included. A manual search for additional pertinent studies and review articles using references from retrieved articles was also completed.
| Inclusion criteria
The eligibility criteria included the following:
1. Cohort study (prospective or retrospective) or case-control study reporting the incidence of MAE in BrS patients with and without SCN5A mutations 2. Calculation of relative risk, hazard ratio, odds ratio, incidence ratio, or standardized incidence ratio with 95% confidence intervals (CI) or provision of sufficient raw data for these calculations were provided.
Use of BrS participants without SCN5A mutations as controls.
Study eligibility was independently determined by two investigators (JC and PM) and any discrepancies were resolved by mutual consensus. Newcastle-Ottawa quality assessment scale was used to evaluate each study's quality. The scale uses a star system (0-9) to evaluate three domains: recruitment and selection of the participants, similarity and comparability between the groups, and ascertainment of the outcome of interest among cohort studies. Higher scores represent higher study quality (Stang, 2010) .
| Data extraction
A standardized data collection form was used to obtain the following information from each study: title of study, name of first author, year of study, year of publication, country of origin, number of participants, demographic data of participants, method used to identify cases and controls, methods used to diagnose the outcomes of interest (SCN5A mutation and MAE), methods to verify if the variants were disease-causing, and average duration of follow-up with confounders that were adjusted effect estimates with 95% CI and covariates that were adjusted in the multivariable analysis.
To ascertain the accuracy, all investigators independently performed this data extraction process. Any data discrepancy was resolved by referring back to the original articles.
| Statistical analysis
We performed a meta-analysis of the included cohort studies using a random-effects model. The extracted studies were excluded from the analysis if they did not present an outcome in each intervention group or did not have enough information required for continuous data comparison. We pooled the point estimates from each study using the generic inverse-variance method of DerSimonian and Laird (1986) . The heterogeneity of effect size estimates across these studies was quantified using the I 2 statistic and Q statistic. For the Q statistic, substantial heterogeneity was defined as p < 0.10. The I 2 statistic ranges in value from 0% to 100% (I 2 < 25%, low heterogeneity; I 2 = 25%-50%, moderate heterogeneity; and I 2 > 50%, substantial heterogeneity; Higgins, Thompson, Deeks, & Altman, 2003) . A sensitivity analysis was performed to assess the influence of the individual studies on the overall results by omitting one study at a time. We used a sequential omitting strategy, as described by Patsopoulos, Evangelou, and Ioannidis (2008) , to examine whether overall estimates were influenced by the substantial heterogeneity observed. Publication bias was assessed using a funnel plot and Egger's regression test (p < 0.05 was considered significant; Sterne & Egger, 2001 ).
Potential sources of heterogeneity from clinical characteristics were analyzed with subgroup analysis and were compared with meta-regression. Pooled risk ratio (RR), sensitivity analysis, funnel plot, and forest plot were performed using Review Manager Egger test was performed using the Stata SE 14.1 software from StataCorp LP.
| RE SULTS
| Description of included studies
Our search strategy yielded 382 potentially relevant articles (227 articles from EMBASE and 155 articles from MEDLINE). After exclusion of duplicates, 253 articles underwent title and abstract review.
Two hundred and eleven articles were excluded at this stage as they
were not cohort studies and they were not conducted in patients with BrS, leaving 42 articles for full-length article review. Thirty-five articles were excluded because they did not report the outcome of interest or they did not have a control group. Therefore, seven prospective cohort studies of BrS patients were included in this metaanalysis. Figure 1 outlines the search and literature review process.
The clinical characteristics and summary of included studies are provided in Table 1 . The Newcastle-Ottawa scales of the included studies are described in the Table 1 .
| Meta-analysis results
Seven studies from March 2002 to October 2017 were included in this meta-analysis involving 1,049 subjects with BrS (302 patients with SCN5A mutations and 747 patients without SCN5A mutations). Five studies revealed an increased MAE among BrS patients with SCN5A mutations (Andorin et al., 2016; Conte et al., 2015; Makarawate et al., 2017; Nishii et al., 2010; Yamagata et al., 2017) with one of the five studies (Makarawate et al., 2017) Figure 2 .
In subgroup analysis among ethnicities, three studies (two studies from Japan and one study from Thailand) were included in Asian populations (Makarawate et al., 2017; Nishii et al., 2010; Yamagata et al., 2017) involving 486 subjects with BrS (80 patients with SCN5A mutations and 406 patients without SCN5A mutations). All three studies revealed increased MAE among BrS patients with SCN5A mutations (Makarawate et al., 2017; Nishii et al., 2010; Yamagata et al., 2017) with one study (Makarawate et al., 2017) Figure 2 .
In Caucasian cohorts, four studies were included in the analysis (Andorin et al., 2016; Conte et al., 2015; Eckardt et al., 2005; Priori et al., 2002) 56 (28) 89 (42) 65 (60) 130 (73.8) 21 (20) 40 (100) 187 (45) (Continued) (RR = 0.78, 95% CI: 0.34-1.80, p = 0.57, I 2 = 15%). A forest plot of this meta-analysis is shown in Figure 2 .
In symptomatic BrS patients, there were four studies (Andorin et al., 2016; Makarawate et al., 2017; Nishii et al., 2010; Yamagata et al., 2017) Figure 3c .
| Sensitivity analysis
To assess the stability of the result, we conducted a sensitivity analysis by omitting one study at a time. We used a sequential omitting strategy, as described by Patsopoulos and colleagues, to examine whether overall estimates were influenced by the substantial heterogeneity observed (Patsopoulos et al., 2008 (Figure 5 ).
In the subgroup analysis, none of the results was significantly altered.
| Publication bias
To investigate potential publication bias, we examined the contourenhanced funnel plot of the included studies in assessing change in the log odd ratio of death or composite outcome (Figure 4) . The vertical axis represents study size (standard error) while the horizontal axis represents effect size (log odds ratio). 
TA B L E 1 (Continued)
BrS, and spontaneous type-1 pattern subgroups as there were only two studies. Meta-regression confirmed that the studies published before 2010 were significant sources of heterogeneity (p = 0.035) but available verification status of SCN5A disease-causing variants was not a significant source of heterogeneity (p = 0.968). only symptomatic patients were included; and only two polymorphisms were identified (R1193Q and H558R). A degree of pathogenicity of these two variants were questionable and may be more, or less, malignant than those reported in other studies.
| D ISCUSS I ON
It is well recognized that a history of aborted cardiac arrest is one of the strongest predictors for future MAE in BrS patients (Eckardt et al., 2005; Priori et al., 2002; Probst et al., 2010; Yamagata et al., 2017) ; in fact, the current guidelines recommends that those who survive episodes of cardiac arrest should undergo ICD implantation (Priori et al., 2013) as the risk of subsequent cardiac events was highest among this patient subgroup and was estimated as 7.7% per year in one study (Probst et al., 2010) . On the other hand, the risk of MAE in asymptomatic BrS individuals is low, approximately 0.5% per year (Probst et al., 2010) . Other reported potential risks include male sex, presence of spontaneous ST-segment elevation in the precordial leads, positive electrophysiological study, F I G U R E 2 Forest plot of the included studies assessing the association between SCN5A mutation and major arrhythmic events and fatal arrhythmia among Asian, Caucasian, and overall analysis presence of atrial fibrillation, and certain electrocardiographic conduction abnormalities such as prolonged P-wave, prolonged QRS duration, and fragmented QRS (Chen et al., 1998; Gehi et al., 2006; Priori et al., 2002; Rattanawong, Riangwiwat, et al., 2017; Yamagata et al., 2017) . Priori et al. demonstrated that the presence of both syncope and spontaneous ST-segment elevation has F I G U R E 3 Forest plot of the included studies assessing the association between SCN5A mutation and major arrhythmic events and fatal arrhythmia in subgroup analysis of (a) symptomatic BrS, (b) asymptomatic BrS, and (c) spontaneous type-1 BrS F I G U R E 4 Funnel plot of SCN5A mutation and major arrhythmic events in (a) overall analysis, Asian, and Caucasian, (b) symptomatic, (c) asymptomatic, and (d) spontaneous type-1. Circles represent observed published studies a sensitivity of 36% and a high specificity of 94% in predicting the occurrence of cardiac arrest in BrS patients (Priori et al., 2002) . On the contrary, many studies have assessed family history of sudden cardiac death as a predictor for poorer outcomes, and the results were reproducibly unrevealing (Gehi et al., 2006; Makarawate et al., 2017; Nishii et al., 2010; Priori et al., 2002) . Clinicians have long been intrigued by the concept of using SCN5A mutation status to predict MAE in BrS patients.
Adler et al. (2016) have recently reviewed the risk stratification strategy in patients with BrS and stated that, according to the large registries, the use of genetic data to risk stratify BrS patients are not well-defined and challenging. Even though a risk score based on the mutations and other polymorphisms has been developed (Sommariva et al., 2013) , the authors suggested that the tool needs to be validated before being adopted. In 2006, Gehi et al. analyzed 383 patients from two publications (Eckardt et al., 2005; Priori et al., 2002) and found no link between SCN5A mutations and increased risk of sudden cardiac death, syncope, or ICD shock (relative risk 0.60, CI: 0.29-1.26). We speculate that the nonsignificant result in their study was due to a lower number of recruited patients, lower number of included studies, and limited power to identify a minimal increase in risk. To our knowledge, our study is the first meta-analysis to demonstrate the potential utilization of SCN5A mutation in the risk stratification scheme, particularly in certain subgroups, of BrS.
SCN5A mutations were reported in approximately 14%-26% of
BrS patients and known as the most common BrS-associated gene (Chen et al., 1998; Yamagata et al., 2017) . Almost 300 SCN5A mutations have been identified in BrS, including missense mutations, nonsense mutations, nucleotide insertion/deletions, and splice site mutations, and the number of SCN5A mutations is still increasing (Juang & Horie, 2016 ). An SCN5A mutation does not necessarily indicate BrS ). The functional loss of NaV1.5 cardiac sodium channel with subsequent reduced sodium current is typically described in BrS patients with SCN5A mutations (Juang & Horie, 2016) . This is supported by the fact that BrS-associated SCN5A mutations usually result in frameshift errors, splice-site defects, or premature stop codons that lead to nonfunctional channels (Chen et al., 1998) . BrS-causing missense mutations were observed to be nonfunctional due to either disrupted protein trafficking to the cell membrane or impaired sodium conductance (George, 2005) .
Although some missense mutations are functional, they may cause defective gated properties of the channels involving activation and/ or inactivation kinetics (Andorin et al., 2016; Rook et al., 1999) .
Meregalli et al. corroborated this speculation by studying 147 mutation-positive BrS individuals and divided them into three groups:
(a) those with prematurely truncated proteins (group 1); (b) those with missense mutations resulting in significantly (>90%) reduced peak sodium current (group 2); and (c) those with missense mutations resulting in mildly (≤90%) reduced peak sodium current (group 3) (Meregalli et al., 2009) . They found that patients in group 1 and group 2, in which drastic peak sodium current were noted, developed a more severe conduction disorders. The underlying electrophysiological mechanisms of how altered sodium current causes BrS are still under investigation, and two models have been proposed (Meregalli, Wilde, & Tan, 2005) . In the "repolarization disorder" model, the defective sodium channel reduces the myocardial sodium current and causes a disproportionate shortening of the right ventricular epicardial action potentials, leading to an exaggerated transmural (i.e., epicardium-to-myocardium) voltage gradient and the characteristics finding on electrocardiogram (George, 2005; Juang & Horie, 2016; Smits et al., 2002) . The "depolarization dis- as arrhythmogenic mechanisms in BrS (Nademanee et al., 2015) . Priori SG et al. (2002) Meta-analysis random-effects estimates (exponential form)
Study omitted
When compared to SCN5A-negative BrS patients, those with SCN5A mutations tend to exhibit significantly longer conduction intervals on electrocardiogram, such as PQ or His-to-ventricle intervals, and more fragmented QRS, both at baseline and throughout the follow-up (Makarawate et al., 2017; Nishii et al., 2010; Rattanawong, Riangwiwat, et al., 2017; Smits et al., 2002; Yokokawa et al., 2007) .
These parameters were also predictive of the presence of the mutation: for example, PQ duration of ≥210 milliseconds had a sensitivity of 48% and a specificity of 98% for detecting SCN5A mutation in BrS patients (Smits et al., 2002) . The prognostic value of SCN5A status has become more apparent in recent well-designed studies.
In a study of 415 BrS patients reported by Yamagata et al. (2017) , SCN5A mutation carriers tended to experience their cardiac events more frequently and at younger ages. Apart from history of aborted cardiac arrest, harboring the mutation was the only independent predictor of MAE, with a hazard ratio of 2.0 (95% CI: 1.0-3.8). They also found that mutations in the pore region of the NaV1.5 cardiac sodium channel were more associated with MAE (Yamagata et al., 2017) . Hence, these studies have confirmed the genotype-pheno- mutations (Meregalli et al., 2009 ). Moreover, age-related fibrosis has also been seen in mouse models of SCN5A mutation (Jeevaratnam et al., 2012; Royer et al., 2005) . Therefore, SCN5A mutations may contribute to substrate changes which may be treatable with epicardial ablation. In our study, we found that SCN5A mutations in symptomatic BrS is twofold associated with MAE compared to symptomatic Brugada syndrome without SCN5A mutations. SCN5A mutation status may therefore enhances risk stratification of symptomatic Brugada syndrome.
| Limitations
Although most recruited studies were of high quality, we recognize there are some limitations to our analysis. First, the studies are heterogeneous as discussed earlier. The potential sources of heterogeneity include age and gender of participants, definitions of MAE in each study, follow-up duration, inclusion of mutation-positive screened family members or of asymptomatic carriers, geographic difference, and recruiting protocol (e.g., multicenter registry vs. single center).
Second, genetic heterogeneity also existed among studies. For instance, Yamagata et al. (2017) identified 55 different mutations in 60 affected individuals in their multicenter cohort, whereas Makarawate et al. (2017) found only two different mutated alleles in 13 SCN5A mutation carriers. However, since BrS is uncommon and large-scale genetic studies have been rarely performed, the possibility of smallstudy bias due to the small number of included studies and small sample size is not negligible. A larger study with a more homogeneous population is needed to confirm our results. Unfortunately, there was not enough information reported in two articles that we could use to calculate multivariate adjusted RR. Risk ratios were calculated based on number of the patients without multivariate adjustment. Third, large genomic imbalances, such as copy-number variants (CNVs) in SCN5A, were recently shown to underlie a portion of genotype-negative patients and should be screened (Mademont-Soler et al., 2016; Sonoda et al., 2018) . However, all of the recruited studies have used traditional methods of sequencing which could not detect CNVs; hence, the control group may include those CNV-harboring sequencing-negative patients and did not truly represent unaffected individuals. Fourth, three (Makarawate et al., 2017; Priori et al., 2013; Yamagata et al., 2017) of seven studies reported information on how the authors verified if the variants were disease-causing (Table 1) ;
however, meta-regression confirmed that verification status of SCN5A disease-causing variants was not a significant source of heterogeneity in overall results. Lastly, this is a meta-analysis of observational studies with the inherent limitation of being able to confirm an association, but not a causal relationship.
| CON CLUS ION
From our study, we found that mutation status may help predict MAE and guide treatment decisions in certain subgroups of BrS, especially in Asian population, symptomatic patients, and individuals with spontaneous type-1 Brugada pattern. The presence of SCN5A mutations may be an important tool to prognosticate risk and guide treatment in patients with BrS in the future.
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